![]() PRISM extracts were screened for activity against strains of methicillin-susceptible S. Medicinal Garden by upper-division undergraduate students. The Principal Rhode Island Secondary Metabolite (PRISM) library is a botanical extract library generated from specimens in the URI Heber W. Medicinal plants have shown promise as sources of new small molecule therapeutics with potential uses against pathogenic infections. ![]() The overuse of antibiotics has contributed to mutations leading to the emergence of methicillin-resistant Staphylococcus aureus, and there is a critical need for the discovery and development of new antibiotics to evade drug resistant bacteria. One analyst has rated the stock with a sell rating, twelve have issued a hold rating and seven have assigned a buy rating to the company.Infections caused by the bacterium Staphylococcus aureus continue to pose threats to human health and put a financial burden on the healthcare system. Finally, initiated coverage on shares of Sage Therapeutics in a research report on Thursday, March 31st. Mizuho cut their price objective on shares of Sage Therapeutics from $41.00 to $37.00 in a research report on Wednesday, May 4th. Canaccord Genuity Group cut their price objective on shares of Sage Therapeutics from $95.00 to $64.00 and set a "buy" rating on the stock in a research report on Friday, February 25th. Morgan Stanley cut their price objective on shares of Sage Therapeutics from $61.00 to $57.00 and set an "equal weight" rating on the stock in a research report on Thursday, March 10th. SVB Leerink cut their price objective on shares of Sage Therapeutics from $60.00 to $50.00 and set a "market perform" rating on the stock in a research report on Friday, February 25th. SAGE has been the topic of a number of analyst reports. During the same quarter in the previous year, the business earned ($1.64) EPS. 1% compared to the same quarter last year. The company's quarterly revenue was down. Sage Therapeutics had a negative net margin of 7,676.91% and a negative return on equity of 27.23%. The company had revenue of $1.58 million for the quarter, compared to the consensus estimate of $3.23 million. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, missing analysts' consensus estimates of ($2.06) by ($0.01). Sage Therapeutics ( NASDAQ:SAGE - Get Rating) last announced its quarterly earnings data on Tuesday, May 3rd. Zacks' sales calculations are a mean average based on a survey of research firms that follow Sage Therapeutics. For the next financial year, analysts expect that the company will post sales of $111.81 million, with estimates ranging from $8.32 million to $269.85 million. On average, analysts expect that Sage Therapeutics will report full-year sales of $7.41 million for the current fiscal year, with estimates ranging from $6.10 million to $13.04 million. The company is scheduled to announce its next earnings report on Monday, January 1st. Sage Therapeutics reported sales of $1.64 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 236.6%. Twelve analysts have made estimates for Sage Therapeutics' earnings, with the highest sales estimate coming in at $47.00 million and the lowest estimate coming in at $1.50 million. ( NASDAQ:SAGE - Get Rating) to announce $5.52 million in sales for the current fiscal quarter, Zacks reports. 7 Health Care Stocks to Buy Even if the Economy Gets SickĮquities research analysts expect Sage Therapeutics, Inc.7 Small-Cap Stocks that Present Long-Term Growth Opportunities.7 Transportation Stocks That Can Keep Your Portfolio Moving Forward.7 Retail Stocks That May Still Ring the Register. ![]() 7 Consumer Discretionary Stocks That May Defy Expectations.7 Outdoor Living Stocks to Buy Before Investors Go Away For the Summer.7 NFT Related Stocks That Are Helping to Drive This Trend.7 Agricultural Technology Stocks to Buy as Commodity Prices Remain Volatile.7 Dividend Stocks to Buy When Safety is Your Top Priority.7 Stagflation Stocks to Help Navigate Periods of Low Growth.7 Commodities ETFs to Help Build a Hedge Against Inflation.Commercial Metals Company Is Ready To Rebound.The Q2 Earnings Season Could Be A Bloodbath.Palo Alto Networks: Pioneering AI in Cybersecurity.Honda's Stock Continues To Fly Under The Radar.eBay’s Long Term Fundamentals Are Intact If You Can Stomach Short Term Volatility.Ride Out The Recession With These Dividend Kings.The Trader's Guide to Equities Research.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |